Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses
Sara Adibfar(Kermanshah University of Medical Sciences), Farhad Jadidi-Niaragh(Tabriz University of Medical Sciences), Jamshid Gholizadeh Navashenaq(Bam University of Medical Sciences), Hamed Mohammadi(Tehran University of Medical Sciences), Sepideh Izadi(German Cancer Research Center), Ali Masjedi(Tabriz University of Medical Sciences), Atefeh Nazer(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Bentolhoda Rashidi(Tabriz University of Medical Sciences), Hadi Hassannia(Mazandaran University of Medical Sciences), Vahid Karpisheh(Tabriz University of Medical Sciences), Hanieh Tarokhian(Kermanshah University of Medical Sciences)
Cited by 15
Related Papers
CAR T cells in solid tumors: challenges and opportunities
|Stem Cell Research & Therapy|2021|573
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
The paradox of Th17 cell functions in tumor immunity
|Cellular Immunology|2017|222
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202